Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITDAEPS (Basic)EPS (Weighted Average and Diluted)Income towards Parent CompanyInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOther Operating ExpensesProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Summit Therapeutics (SMMT) EPS (Basic) (2016 - 2026)

Summit Therapeutics filings provide 13 years of EPS (Basic) readings, the most recent being -$0.24 for Q1 2026.

  • Quarterly EPS (Basic) fell 166.67% to -$0.24 in Q1 2026 from the year-ago period, while the trailing twelve-month figure was -$1.59 through Mar 2026, down 354.29% year-over-year, with the annual reading at -$1.44 for FY2025, 364.52% down from the prior year.
  • EPS (Basic) hit -$0.24 in Q1 2026 for Summit Therapeutics, up from -$0.28 in the prior quarter.
  • Across five years, EPS (Basic) topped out at -$0.01 in Q4 2023 and bottomed at -$1.43 in Q1 2023.
  • Average EPS (Basic) over 5 years is -$0.23, with a median of -$0.09 recorded in 2024.
  • The largest annual shift saw EPS (Basic) tumbled 853.33% in 2023 before it surged 95.8% in 2024.
  • Summit Therapeutics' EPS (Basic) stood at -$0.04 in 2022, then soared by 75.0% to -$0.01 in 2023, then tumbled by 800.0% to -$0.09 in 2024, then plummeted by 211.11% to -$0.28 in 2025, then rose by 14.29% to -$0.24 in 2026.
  • Per Business Quant, the three most recent readings for SMMT's EPS (Basic) are -$0.24 (Q1 2026), -$0.28 (Q4 2025), and -$0.31 (Q3 2025).